Select publications

Baum M et al; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract

Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Proc SABCS 2003(Suppl 1);Abstract 3.

Carlson RW, Henderson IC. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res Treat 2003;80(Suppl 1):19-26. Abstract

Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Coleman R et al. Association between prior chemotherapy and the adverse event (AE) profile of adjuvant anastrozole (A) or tamoxifen (T): A retrospective analysis from the ATAC trial. Proc ASCO 2004;Abstract 767.

Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

Distler W et al. Impact of age on the gynecologic adverse event (AE) profile of anastrozole (A) or tamoxifen (T) in the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2004;Abstract 770.

Dixon JM. Exemestane and aromatase inhibitors in the management of advanced breast cancer. Expert Opin Pharmacother 2004;5(2):307-16. Abstract

Gnant M et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial. Breast Cancer Res Treat 2002;Abstract 12.

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract

Goss PE et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Proc ASCO 2004;Abstract 847.

Henderson IC et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer. J Clin Oncol 2003;21(6):976-83. Abstract

Ingle JN. Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clin Cancer Res 2004;10(1 Pt 2):362S-7S. Abstract

Locker GY et al. The time course of bone fractures observed in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. Proc ASCO 2003;Abstract 98.

Mouridsen HT et al. Challenges in the endocrine management of breast cancer. Breast 2003;12 (Suppl 2):S2-19. Abstract

Paridaens R et al; European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC). Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14(9):1391-8. Abstract

Whelan T et al. Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. Proc ASCO 2004;Abstract 517.